AR118641A1 - Compuestos, composiciones y métodos - Google Patents
Compuestos, composiciones y métodosInfo
- Publication number
- AR118641A1 AR118641A1 ARP200101008A ARP200101008A AR118641A1 AR 118641 A1 AR118641 A1 AR 118641A1 AR P200101008 A ARP200101008 A AR P200101008A AR P200101008 A ARP200101008 A AR P200101008A AR 118641 A1 AR118641 A1 AR 118641A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- independently
- heterocyclyl
- alkylsulfonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832775P | 2019-04-11 | 2019-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118641A1 true AR118641A1 (es) | 2021-10-20 |
Family
ID=72752101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101008A AR118641A1 (es) | 2019-04-11 | 2020-04-08 | Compuestos, composiciones y métodos |
Country Status (19)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3086182A1 (en) | 2017-12-20 | 2019-06-27 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
| AU2021371697B2 (en) * | 2020-10-29 | 2024-10-24 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof |
| CN116120291B (zh) * | 2023-04-11 | 2023-06-30 | 英矽智能科技(上海)有限公司 | 吲唑类化合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101566091B1 (ko) | 2010-11-10 | 2015-11-04 | 에프. 호프만-라 로슈 아게 | Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체 |
| PT3472153T (pt) * | 2016-06-16 | 2021-12-31 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos |
| WO2018217946A1 (en) * | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CA3086182A1 (en) | 2017-12-20 | 2019-06-27 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
-
2020
- 2020-04-08 AR ARP200101008A patent/AR118641A1/es unknown
- 2020-04-10 SG SG11202111058XA patent/SG11202111058XA/en unknown
- 2020-04-10 US US17/602,480 patent/US12358896B2/en active Active
- 2020-04-10 MX MX2021012392A patent/MX2021012392A/es unknown
- 2020-04-10 WO PCT/US2020/027742 patent/WO2020210684A1/en not_active Ceased
- 2020-04-10 MA MA055624A patent/MA55624A/fr unknown
- 2020-04-10 CN CN202080041217.0A patent/CN113939294A/zh active Pending
- 2020-04-10 DK DK20787582.4T patent/DK3953348T3/da active
- 2020-04-10 JP JP2021559818A patent/JP7623294B2/ja active Active
- 2020-04-10 KR KR1020217036412A patent/KR102962366B1/ko active Active
- 2020-04-10 AU AU2020272045A patent/AU2020272045B2/en active Active
- 2020-04-10 ES ES20787582T patent/ES3018383T3/es active Active
- 2020-04-10 IL IL287120A patent/IL287120B2/en unknown
- 2020-04-10 TW TW109112173A patent/TWI851710B/zh active
- 2020-04-10 BR BR112021020027A patent/BR112021020027A2/pt unknown
- 2020-04-10 EA EA202192530A patent/EA202192530A1/ru unknown
- 2020-04-10 EP EP20787582.4A patent/EP3953348B1/en active Active
- 2020-04-10 CA CA3136447A patent/CA3136447A1/en active Pending
-
2021
- 2021-10-05 ZA ZA2021/07499A patent/ZA202107499B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES3018383T3 (es) | 2025-05-16 |
| EP3953348B1 (en) | 2024-12-18 |
| CN113939294A (zh) | 2022-01-14 |
| AU2020272045A1 (en) | 2021-10-28 |
| IL287120B1 (en) | 2025-02-01 |
| BR112021020027A2 (pt) | 2021-12-07 |
| TWI851710B (zh) | 2024-08-11 |
| JP7623294B2 (ja) | 2025-01-28 |
| DK3953348T3 (da) | 2025-03-17 |
| WO2020210684A1 (en) | 2020-10-15 |
| JP2022526015A (ja) | 2022-05-20 |
| KR102962366B1 (ko) | 2026-05-11 |
| TW202104213A (zh) | 2021-02-01 |
| AU2020272045B2 (en) | 2026-01-15 |
| EP3953348A1 (en) | 2022-02-16 |
| MX2021012392A (es) | 2021-11-12 |
| CA3136447A1 (en) | 2020-10-15 |
| EA202192530A1 (ru) | 2022-03-15 |
| IL287120B2 (en) | 2025-06-01 |
| US20220220094A1 (en) | 2022-07-14 |
| EP3953348A4 (en) | 2023-01-18 |
| SG11202111058XA (en) | 2021-11-29 |
| ZA202107499B (en) | 2022-06-29 |
| IL287120A (en) | 2021-12-01 |
| KR20210151887A (ko) | 2021-12-14 |
| US12358896B2 (en) | 2025-07-15 |
| MA55624A (fr) | 2022-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127309A2 (es) | Derivados de piridazinona | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR065354A1 (es) | Derivados de 2-aminopirimidina, un metodo para su preparacion, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de histamina h4. | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| PE20190504A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR088246A1 (es) | Derivados de etinilo | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco | |
| AR120649A1 (es) | Antagonistas del receptor de crf y métodos de uso | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| AR123543A1 (es) | DERIVADOS DE 2-(3-PIRIDIN-2-IL-4-QUINOLIN-4-IL-PIRAZOL-1-IL)-ACETAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b-1 / ALK5 | |
| AR109651A1 (es) | Compuestos de piridina y pirazina como inhibidores de ripk2 | |
| AR099690A1 (es) | Ureas asimétricas p-sustituidas como moduladoras de la actividad de ghrelina |